Adalimumab effectiveness for the treatment of ankylosing spondylitis is maintained for up to 2 years: long-term results from the ATLAS trial
Articolo
Data di Pubblicazione:
2009
Citazione:
Adalimumab effectiveness for the treatment of ankylosing spondylitis is maintained for up to 2 years: long-term results from the ATLAS trial / Van Der Heijde, D; Schiff, M. H; Sieper, J; Kivitz, A. J; Wong, R. L; Kupper, H; Dijkmans, B. A. C; Mease, P. J; Davis, J. C; Atlas, ; Salvarani, Carlo. - In: ANNALS OF THE RHEUMATIC DISEASES. - ISSN 0003-4967. - 68:6(2009), pp. 922-929. [10.1136/ard.2007.087270]
Abstract:
To determine the long-term effect of adalimumab on patients with ankylosing spondylitis (AS) who participated in the Adalimumab Trial Evaluating Long-Term Efficacy and Safety in AS (ATLAS), a randomised, double-blind, placebo controlled, 24-week trial.
Tipologia CRIS:
Articolo su rivista
Keywords:
Adolescent; Adult; Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antirheumatic Agents; Double-Blind Method; Female; Follow-Up Studies; Health Status Indicators; Humans; Male; Middle Aged; Quality of Life; Remission Induction; Spine; Spondylitis, Ankylosing; Treatment Outcome
Elenco autori:
Van Der Heijde, D; Schiff, M. H; Sieper, J; Kivitz, A. J; Wong, R. L; Kupper, H; Dijkmans, B. A. C; Mease, P. J; Davis, J. C; Atlas, ; Salvarani, Carlo
Link alla scheda completa:
Link al Full Text:
Pubblicato in: